Polar Capital’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Polar Capital’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,900,000	Closed	-$7.03M	–	289
2017 Q4	$7.03M	Buy	1,900,000 +650,000	+52%	+$2.66M	0.07%	185
2017 Q3	$5.11M	Buy	1,250,000 +250,000	+25%	+$956K	0.06%	197
2017 Q2	$3.71M	Buy	1,000,000 +450,000	+82%	+$1.79M	0.05%	203
2017 Q1	$2.28M	Buy	+550,000	New	+$2.31M	0.03%	226

Polar Capital's CASC Position: Q1 2018 in Review

Polar Capital sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 1,900,000 shares — an estimated $7.03M sold.

Polar Capital first reported a position in CASC in Q1 2017 and held it in 4 quarters. The position peaked at $7.03M in Q4 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

Polar Capital reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Polar Capital sold 1,900,000 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $7.03M.
Polar Capital first reported a position in Cascadian Therapeutics, Inc. in Q1 2017 and held it in 4 quarters.
Polar Capital's Cascadian Therapeutics, Inc. position peaked at $7.03M in Q4 2017.
1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Polar Capital's 13F filing for Q1 2018, filed 15 May 2018.